Report overview
These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein.
This report aims to provide a comprehensive presentation of the global market for Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer. This report contains market size and forecasts of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in global, including the following market information:
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Pertuzumab Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer include Roche, BOC Sciences, LGM Pharma, Biotechnica Pharma Global, KinBio and Merck, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Segment Percentages, by Type, 2022 (%)
Pertuzumab
Trastuzumab
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Segment Percentages, by Application, 2022 (%)
Combination Therapy
Mono Therapy
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
BOC Sciences
LGM Pharma
Biotechnica Pharma Global
KinBio
Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer, market overview.
Chapter 2: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market size in revenue.
Chapter 3: Detailed analysis of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
